Apimeds Pharmaceuticals US, Inc. (APUS)
ASE – Real Time Price. Currency in USD
0.90
+0.04 (4.90%)
At close: Jun 26, 2026, 4:00 PM EDT
0.91
+0.01 (1.11%)
After-hours: Jun 26, 2026, 7:30 PM EDT
Find any stock by ticker or company name

ASE – Real Time Price. Currency in USD
0.90
+0.04 (4.90%)
At close: Jun 26, 2026, 4:00 PM EDT
0.91
+0.01 (1.11%)
After-hours: Jun 26, 2026, 7:30 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Cash reserves $9.0M barely cover the upcoming debt maturities $9.5M
Total current liabilities $14.6M surpass Total current assets $13.2M, signaling liquidity issues
Debt-to-equity ratio (0.1) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (-4.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$2.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.90 | 2.52 | 6.0 | |
| Quick ratio | 0.90 | 1.78 | 6.0 | |
| Debt to Equity | 0.08 | -0.80 | 9.0 | |
| Debt to Assets | 0.07 | 0.73 | 9.0 | |
| Interest coverage | -4.74 | -13.90 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | -6K | -26K |
| Operating Income | -640K | -747K | -1M | -12M | -16M |
| Net Income | -669K | -778K | -1M | -6M | -41M |
| EBITDA | -640K | -747K | -1M | -12M | -16M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | 49.73 | 1.0 | |
| Operating margin % | N/A | 0.39 | 1.0 | |
| Net margin % | N/A | -50.32 | 1.0 | |
| EBITDA margin % | N/A | -16.02 | 1.0 | |
| Cash flow margin % | N/A | 124.71 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | N/A | 1.0 |
| Next year | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -2934.71 | N/A | 43.95 | 5.5 |
| Y/Y | 999 | -8612.74 | N/A | -10496.35 | 3.3 |
| 3y average | 999 | -142.24 | N/A | -393.83 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |